New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
08:56 EDTLCILannett decline on Connecticut probe seems overdone, says Roth Capital
After Lannett fell 17% following the disclosure that it had received subpoenas from Connecticut regarding the pricing of digoxin, Roth Capital does not expect the state to take any further action against the company. The firm does not believe that there has been any collusion on digoxin prices. It keeps a $45 price target and Buy rating on the shares.
News For LCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
09:57 EDTLCILannett management to meet with Oppenheimer
Meeting to be held in Texas on October 8 hosted by Oppenheimer.
September 30, 2014
15:39 EDTLCIClass action lawsuit against Lannett voluntarily dismissed without prejudice
Subscribe for More Information
September 22, 2014
07:29 EDTLCILannett launches Oxycodone Hydrochloride Oral Solution
Lannett Company announced that it has commenced shipping its recently approved Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL. According to IMS, annualized sales of Oxycodone Hydrochloride Oral Solution USP, 100 mg per 5 mL, at Average Wholesale Price were approximately $43M. “We previously expected to begin marketing our Oxycodone Hydrochloride Oral Solution product in the second half of our fiscal year,” said Arthur P. Bedrosian, president and CEO of Lannett. “The earlier than anticipated launch combined with continued strong sales of our Digoxin product in the first quarter provide us with additional confidence to reaffirm our financial guidance for the fiscal 2015 full year.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use